Eli Lilly & Co. has prepared and tested glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of dementia, hyperlipidemia, hypertension, obesity, cerebral infarction, Parkinson’s disease, and type 1 and type 2 diabetes, among others.